IOVANCE BIOTHERAPEUTICS INC

For the period ended Dec 31, 2024. Filed Feb 27, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 27, 2025

IOVA$8.17+1.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(In thousands, except share and per share information)


· December 31, · · December 31,
· 2024 · 2023
ASSETS · · ·
· · ·
Current Assets · · ·
Cash and cash equivalents	$115,694	$114,888
Trade accounts receivable	69,340	151
Short-term investments	208,087	164,979
Inventory	51,520	10,372
Prepaid expenses and other assets	12,377	17,458
Total Current Assets	457,018	307,848

Property and equipment, net	109,081	114,030
Intangible assets, net	282,398	229,258
Operating lease right-of-use assets	55,201	62,515
Restricted cash	6,359	66,430
Long-term assets	369	270
Total Assets	$910,426	$780,351

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current Liabilities
Accounts payable	$27,509	$33,123
Accrued expenses and other liabilities	81,936	69,406
Operating lease liabilities	12,896	7,777
Total Current Liabilities	122,341	110,306

Non-Current Liabilities
Operating lease liabilities – non-current	44,365	67,085
Deferred tax liabilities	32,315	17,347
Long-term note payable	1,000	1,000
Total Non-Current Liabilities	77,680	85,432
Total Liabilities	200,021	195,738

Commitments and contingencies

Stockholders’ Equity
Series A Convertible Preferred stock, $0.001 par value; 17,000 shares designated, 194 shares issued and outstanding as of December 31, 2024 and December 31, 2023	—	—
Series B Convertible Preferred stock, $0.001 par value; 11,500,000 shares designated, 2,842,158 shares issued and outstanding as of December 31, 2024 and December 31, 2023	3	3
Common stock, $0.000041666 par value; 500,000,000 shares authorized, 305,252,194 and 256,135,715 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively	13	11
Accumulated other comprehensive loss (income)	(1,046)	2,526
Additional paid-in capital	3,095,987	2,594,448
Accumulated deficit	(2,384,552)	(2,012,375)
Total Stockholders’ Equity	710,405	584,613
Total Liabilities and Stockholders’ Equity	$910,426	$780,351

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.